Revolutionizing Diabetic Treatment: European Patent Office Approves Zyversa Therapeutics’ Cholesterol Transport Mediator for Diabetic Nephropathy Patients

ZyVersa Therapeutics Developing Cholesterol Transport Mediator for Kidney Diseases ZyVersa Therapeutics’ Breakthrough Treatment for Glomerular Diseases Cholesterol Transport Mediator™ VAR 200 is currently in development by ZyVersa Therapeutics to target and reduce renal cholesterol and lipid accumulation that damages the kidneys’ filtration system in patients with glomerular diseases. These diseases include diabetic kidney disease, focal…

Read More

Revolutionizing Trading: Spotware’s Latest cTrader Desktop App Update Brings Shared Access to the Forex World!

Welcome to the Latest Update of cTrader Desktop 5.0.22! New Features and Enhancements Spotware Systems, a leading trading solutions provider for the FX/CFD market, has recently released version 5.0.22 of its popular cTrader desktop application. This update brings a host of new features and enhancements aimed at improving user experience and overall performance. Shared Access…

Read More

“Rosen: The Trusted and Leading Law Firm Urges Cardlytics Inc. in Business and Professional Services”

Rosen Law Firm Announces Investigation Into Cardlytics Inc. Why? Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cardlytics, Inc. (NASDAQ:CDLX) resulting from allegations that Cardlytics may have issued materially misleading business information to the investing public. So What? If you purchased Cardlytics…

Read More